The Biggest Biotech Clinical Wins of the Week

See which big biotech and pharmaceutical companies got the best clinical results for the week ending April 4.

Apr 8, 2014 at 10:16AM

Last week was another great one for clinical trial results, although you wouldn't know it looking at biotech and pharmaceutical stock prices. Amgen (NASDAQ:AMGN) released robust data from an enormous late-stage program. Isis Pharmaceuticals (NASDAQ:IONS) furthered the case for RNA antisense therapies. The biggest win of the week belongs to Novartis (NYSE:NVS), the pharmaceutical giant that shocked the industry, and perhaps itself, with a surprise victory just days after a major setback.

Look out Zetia
Amgen continued marching ahead in the race to develop next-generation cholesterol-lowering drugs for the statin intolerant. Last weekend, the company released some detailed data from five Phase 3 studies involving its PCSK9 inhibitor, evolocumab.

The amount of data released could fill volumes, but one trial in particular illustrates evolocumab's potential. The Gauss-2 study compared Amgen's candidate to Merck's (NYSE:MRK) blockbuster Zetia. Last year, Merck recorded $2.66 billion in Zetia sales. It's a popular alternative to statins that reduces the amount of cholesterol absorbed by the small intestine. During the study, evolocumab patients showed a 38 percentage point reduction from baseline in LDL cholesterol compared to Zetia at 12 weeks. The observed 38 percentage point superiority over Zetia was the same for patients receiving both monthly and biweekly evolocumab injections. Nobody likes needles, but if the data continue to be strong, I could see people trading in their daily pills for the more effective monthly injections.

More antisense
Isis and its proprietary development platform was vindicated last January when the FDA approved its first RNA antisense drug, Kynamro. Unfortunately, patients and physicians don't seem interested.

Developed in partnership with Sanofi's (NYSE:SNY) Genzyme, Isis is entitled to between 30% and 50% of Kynamro's profits. The cholesterol-lowering therapy reportedly isn't setting any records, however, with Sanofi expanding its sales force to juice sales.

Last week, one of Isis' 31 candidates took a big step toward commercialization. Its leading unpartnered compound, ISIS-APOCIII, inhibits production of apolipoprotein C3. Patients with too much apo-C3 typically have dangerously elevated levels of triglycerides in their bloodstream. They're at high risk for cardiovascular disease and pancreatitis. With a lack of highly effective therapies, this compound could also reduce elevated levels of red ink on the company's income statements.

In a recent phase 2 trial, patients receiving 200 mg or 300 mg doses ISIS-APOCIII achieved triglyceride reductions of 51% and 64%, respectively. Average levels of high-density lipoprotein -- the good kind -- increased up to 51% and 52%, respectively.

A big concern regarding RNA antisense drugs is potential liver damage. Kynamro comes with a boxed warning citing a risk of hepatic toxicity. There were "no elevations of liver enzymes greater than three times the upper limit of normal" among the 20 patients dosed with ISIS-APOCIII. This is a step in the right direction, but waiting for more safety data from a larger trial is probably a good idea.

Cardiovascular rollercoaster
The cardiology segment at Novartis has been through some ups and downs lately. Serelaxin was one of the first drugs to receive Breakthrough Therapy status from the FDA last year. Late last month, however, the agency's independent advisory committee voted unanimously against it while citing issues with Novartis' pivotal trial design and data.

Just a few days later, Novartis announced what was easily last week's biggest clinical win. An independent data monitoring committee unanimously voted in favor of ending the Paradigm-HF trial early. The 8,436 patient trial pitted the company's LCZ696 against a heart failure treatment standard, the ACE inhibitor enalapril. A statistically significant number of patients with chronic heart failure in the LCZ696 arm lived longer without being hospitalized.

The potential market for an improvement over ACE inhibitors in the treatment of chronic heart failure is hard to overstate. The American Heart Association estimates more than 5 million people in the U.S. now have heart failure. This figure, unfortunately, should continue growing along with the aging population and the increasing population of heart attack survivors. If the existing data holds up to regulator scrutiny, LCZ696 could add a great deal to Novartis' topline in the near term.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers